Next-generation treatment for cancer: genetic vaccines targeting tumor neoantigens delivered through viral vectors.

NousCom is a biotech company founded by experienced entrepreneurs who are developing innovative immunotherapies to combat cancer by activating cancer-specific T cells.

Cancer vaccines come of age

NousCom strategy stems from recent achievements in the fields of checkpoint inhibitors, therapeutic antibodies, cancer vaccines and oncolytic viruses.

We plan to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells, with the expectation to potentiate existing immunotherapies.

Our platform technology is based on three different viral vectors as a powerful toolkit to induce broad and potent anti-cancer T cell responses.

News

13
Nov
2017
NousCom’s Neoantigen-based Vaccine Synergizes with NKTR-214 to Cure Established Tumors in Preclinical Model

06
Nov
2017
NousCom Raises €42 Million Series B Financing